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These regressions were not adjusted for site and gender, since the outcome was too uncommon, and the model did not converge. P-m = person-month. Model predicted differences (ratios) do not always match raw differences (ratios) due to weighting in correlated regression. P-m = person-month. 
eTable 2. Univariable analysis of virologic and clinical efficacy end points by treatment group, in sensitivity analyses that exclude the initial week of each period
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